Is Hruby's scaffold the same as MT-2?

Yes — Ac-Nle4-cyclo[Asp5, D-Phe7, Lys10] alpha-MSH-(4-10)-NH2 is MT-2's architecture written under alpha-MSH numbering rather than the peptide's own.

Why a lactam bridge rather than a disulfide?

A lactam is a permanent amide bond between side chains. It does not reduce or scramble, and needs none of the redox handling a disulfide requires.

What was the 1995 paper's actual finding?

That bulky aromatic residues at position 7 produce antagonists — one residue on the same scaffold decides agonist versus antagonist.

MT-2 (Melanotan II)

A 1995 Paper, and a Structure That Checks Out Exactly

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

Hruby and colleagues published cyclic lactam alpha-melanotropin analogues built on Ac-Nle4-cyclo[Asp5, D-Phe7, Lys10] alpha-MSH-(4-10)-NH2 in the Journal of Medicinal Chemistry in 1995. That framework is MT-2's architecture written under alpha-MSH numbering.

Key facts

Paper: Hruby 1995 (PMID 7658432)
Journal: J Med Chem, 1 September 1995
Institution: University of Arizona
Notable co-author: Roger Cone
Scaffold: Ac-Nle4-cyclo[Asp5, D-Phe7, Lys10]
Parent fragment: alpha-MSH-(4-10)-NH2
Later SAR: Mayorov 2008 (PMID 18088090)

What the scaffold specifies

An acetylated norleucine at alpha-MSH position 4, a lactam bridge closing between an aspartate at position 5 and a lysine at position 10, a D-phenylalanine at position 7, and a C-terminal amide on a fragment spanning residues 4 to 10. Every one of those is a deliberate modification of the natural sequence.

The cross-check against the compound

PubChem's IUPAC name for MT-2 describes a cyclic (2-7) lactam on a seven-residue peptide with N-acetyl norleucine first, D-phenylalanine fourth and a C-terminal amide. Renumber that onto alpha-MSH — MT-2's residues 1 to 7 are alpha-MSH 4 to 10 — and MT-2's lactam positions 2 and 7 become alpha-MSH 5 and 10. Asp5 and Lys10. The two descriptions are the same molecule.

Research material referenced

MT-2 10mg — third-party HPLC tested

View — £19.99

Why that agreement is worth demonstrating

Because this site has repeatedly found identifiers that looked right and were not — a tirzepatide record cited as retatrutide, an organic acid returned for KPV, an approved drug returned for melanotan. Two independent descriptions from unrelated sources agreeing element by element is the opposite situation, and it is worth showing when it happens.

Why a lactam rather than a disulfide

Cyclisation could be achieved with two cysteines forming a disulfide, and many peptides do exactly that. A lactam is a permanent amide bond between side chains — it does not reduce, does not scramble, and does not require the redox handling a disulfide imposes. For a molecule intended to be stable, the lactam is the more robust choice.

The finding the paper is actually about

Not agonists. The title reports that bulky aromatic amino acids at position 7 produce high antagonist potency and selectivity at specific melanocortin receptors. So one residue on the same cyclic scaffold determines whether the compound activates the receptor or blocks it, which is an unusually sharp structure-activity relationship.

Why the research context matters

This was academic medicinal chemistry exploring a newly cloned receptor family, not product development. Roger Cone, a co-author, cloned melanocortin receptors. The scaffold was a research tool for mapping receptor pharmacology, and its later appearance as an unlicensed injectable was not what the chemistry was for.

Extended research context

The MT-2 (Melanotan II) deep dive

Deep dive: the identifier collision that points the wrong way

This site has now found several plausible-looking identifiers that resolve to the wrong molecule. A PubChem record for tirzepatide cited as retatrutide. Thymosin beta-4's CAS quoted as TB-500's. An unrelated organic acid returned for KPV. This one is the most consequential of the set, and the reason is direction. Searching PubChem for melanotan returns CID 16197727 - afamelanotide, at 1,646.8 Da for C78H111N21O19. That is Melanotan I, a linear thirteen-residue peptide, and it is an APPROVED MEDICINE, marketed as Scenesse for erythropoietic protoporphyria. Melanotan II is CID 92432: cyclic, seven residues, 1024.2 Da, 622 Da lighter, and assessed by no regulator anywhere. So the wrong record does not merely mislead about mass. It resolves from an unlicensed compound toward a licensed one, and the sequential naming - I and II - makes them look like versions of a single product rather than the structurally distinct compounds they are. Anyone verifying a certificate by searching the bare name lands on an approved drug's record and may never notice which compound it names.

Deep dive: four stability features in seven residues

PubChem's IUPAC name for CID 92432 is unusually complete and reads as a full specification: N-acetyl-L-norleucyl-L-alpha-aspartyl-L-histidyl-D-phenylalanyl-L-arginyl-L-tryptophyl-L-lysinamide, cyclic (2-7)-peptide. Unpack it and there are four independent protease-resistance features in a molecule of seven residues. A lactam bridge joins the aspartate side chain at position 2 to the lysine side chain at position 7, closing the ring - which both locks conformation for receptor engagement and eliminates the free termini exopeptidases require. Position 4 is D-phenylalanine, the mirror image of the natural form, and proteases are stereospecific enough that they largely cannot process it. The N-terminus is acetylated and the C-terminus amidated, capping both ends. And position 1 is norleucine, which is not among the twenty proteinogenic amino acids at all - so even setting aside the cyclisation and the D residue, this peptide could never have been a gene product. It is a fully synthetic construction rather than a modified natural sequence, and it is among the most chemically robust compounds in this catalogue as a direct result.

Deep dive: why the safety literature is included rather than omitted

There is a published dermatological literature here, and the editorial choice was to state it. Reid and colleagues documented atypical melanocytic naevi following melanotan injection in the Irish Medical Journal in 2013. Eijmael and colleagues published a risk review in the Nederlands Tijdschrift voor Geneeskunde in 2022 - a national medical journal considering the topic worth addressing directly. Case reports have a real limitation: they establish an observation without a denominator, so they cannot establish causation or incidence, which is the same constraint that applies to pharmacovigilance disproportionality signals. But that limitation cuts both ways. A case report is not proof of harm and it is not dismissible either. What makes the absence of better data significant here is that no regulator has assessed this compound - so there is no label, no contraindications, no adverse event reporting requirement and no monitoring framework. The information that would normally exist for an injectable product simply does not, and what is available instead is what individual clinicians chose to publish after seeing something. Presenting the compound without that context would give an incomplete picture of what is actually known.

Research applications

▸Melanocortin receptor pharmacology and selectivity research
▸Cyclic peptide and lactam bridge design studies
▸D-amino acid substitution and protease resistance research
▸Structure-activity work on constrained peptide analogues
▸Comparative work on alpha-MSH derivatives
▸Analytical method development for cyclic peptides

Handling checklist

✓Verify against CID 92432, 1024.2 Da, C50H69N15O9, CAS 121062-08-6
✓Never verify by searching 'melanotan' alone - that returns afamelanotide at 1,646.8 Da
✓Require stereochemistry on the certificate - D-Phe4 is not detectable by mass
✓Protect from light; tryptophan at position 6 is photochemically reactive
✓Store lyophilised, cold, dry and dark
✓Expect no disulfide or oxidation satellites - no cysteine, no methionine
✓Quantification at 280 nm is available thanks to the tryptophan

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Searching PubChem for 'melanotan' to verify identity

Fix: That returns CID 16197727, afamelanotide, at 1,646.8 Da - an approved medicine and a different molecule. Use CID 92432 or search Melanotan II with the numeral.

✗ Treating Melanotan I and II as versions of one compound

Fix: They differ by 622 Da, by six residues, and by whether the peptide is cyclic or linear. Only Melanotan I has been assessed by regulators.

✗ Reading afamelanotide's approval as covering MT-2

Fix: Different molecule, different structure, different evidence, different assessment. Nothing transfers.

✗ Accepting a sequence written without stereochemistry

Fix: L- and D-phenylalanine have identical mass. A peptide with the L form at position 4 is a different compound that mass spectrometry cannot distinguish.

✗ Assuming a non-selective agonist affects only its intended receptor

Fix: Five melanocortin receptors share binding surfaces across different tissues. Engagement elsewhere is the same pharmacology in another place, not a side reaction.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Is Hruby's scaffold the same as MT-2?: Yes — Ac-Nle4-cyclo[Asp5, D-Phe7, Lys10] alpha-MSH-(4-10)-NH2 is MT-2's architecture written under alpha-MSH numbering rather than the peptide's own.
Why a lactam bridge rather than a disulfide?: A lactam is a permanent amide bond between side chains. It does not reduce or scramble, and needs none of the redox handling a disulfide requires.
What was the 1995 paper's actual finding?: That bulky aromatic residues at position 7 produce antagonists — one residue on the same scaffold decides agonist versus antagonist.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More MT-2 (Melanotan II) articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum